Vinpocetine and piracetam exert antinociceptive effect in visceral pain model in mice

Pharmacological Reports

Volumn 58, Issue 5, 2006, Pages 680-691

  Abdel Salam, Omar M E ^a  

^a NATIONAL RESEARCH CENTRE   (Egypt)

Author keywords

Mice; Piracetam; Thermal pain; Vinpocetine; Visceral pain

Indexed keywords

4 AMINOBUTYRIC ACID; ACETIC ACID; ADENOSINE RECEPTOR; ATROPINE; BACLOFEN; BROMOCRIPTINE; DOXAZOSIN; GLIBENCLAMIDE; GUANETHIDINE; HALOPERIDOL; IMIPRAMINE; NALOXONE; PIRACETAM; PRAZOSIN; PROPRANOLOL; SULPIRIDE; THEOPHYLLINE; VINPOCETINE; VINPORAL; YOHIMBINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG POTENTIATION; FORCED SWIMMING TEST; HOT PLATE TEST; IMMOBILIZATION; INHIBITION KINETICS; LOW DRUG DOSE; MALE; MOUSE; NONHUMAN; PHARMACOLOGICAL BLOCKING; THERMAL EXPOSURE; VISCERAL PAIN;

EID: 33751001626     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Bartolini A, Ghelardini C, Fantetti L, Malcangio M, Malmberg-Aiello P, Giotti A: Role of muscarinic receptor subtypes in central antinociception. Br J Pharmacol, 1992, 105, 77-82.
2. Berkenkopf JW, Weichman BM: Production of prostacyclin in mice following intraperitoneal injection of acetic acid, phenylbenzoquinone and zymosan: its role in the writhing response. Prostaglandins, 1988, 36, 693-709.
3. Burkey AR, Carstens E, Jasmin L: Dopamine reuptake inhibition in the rostral agranular insular cortex produces antinociception. J Neurosci, 1999, 19, 4169-4179.
4. Camilleri M, Saslow SB, Bharucha AE: Gastrointestinal sensation: mechanisms and relation to functional gastro intestinal disorders. In: Gastroenterology Clinics of NA: Gastrointestinal Motility in Clinical Practice, vol. 25. Ed. Camilleri M, Saunders, Philadelphia, 1996, 247-258.
5. Cervero F: Neurophysiology of gastrointestinal pain. Baillieres Clin Gastroenterol, 1988, 2, 83-99.
6. Cervero F, Laird JM: Role of ion channels in mechanisms controlling gastrointestinal pain pathways. Curr Opin Pharmacol, 2003, 3, 608-612.
7. Duarte ID, Nakamura M, Ferreira SH: Participation of the sympathetic system in acetic acid-induced writhing in mice. Braz J Med Biol Res, 1988, 21, 341-343.
8. Eckert GP, Cairns NJ, Muller WE. Piracetam reverses hippocampal membrane alterations in Alzheimer's disease. J Neural Transm, 1999, 106, 757-761.
9. Eisenberg E, Carr DB, Chalmers TC. Neurolytic celiac plexus block for treatment of cancer pain: a meta-analysis. Anesth Analg, 1995, 80, 290-295.
10. Fedi M, Reutens D, Dubeau F, Andermann E, D'Agostino D, Andermann F: Long-term efficacy and safety of piracetam in the treatment of progressive myoclonus epilepsy. Arch Neurol, 2001, 58, 781-786.
11. Fischhof PK, Moslinger-Gehmayr R, Herrmann WM, Friedmann A, Russmann DL: Therapeutic efficacy of vincamine in dementia. Neuropsychobiology, 1996, 34, 29-35.
12. Frussa-Filho R, Rocha JB, Conceicao IM: Effects of dopaminergic agents on visceral pain measured by the mouse writhing test. Arch Int Pharmacodyn Ther, 1996, 331, 74-93.
13. Galeotti N, Ghelardini C, Bartolini A: Piracetam and aniracetam antagonism of centrally active drug-induced antinociception. Pharmacol Biochem Behav, 1996, 53, 943-950.
14. Ghelardini C, Galeotti N, Bartolini A: Antinociception induced by amitriptyline and imipramine is mediated by alpha2A-adrenoceptors. Jpn J Pharmacol, 2000, 82, 130-137.
15. Ghelardini C, Malmberg-Aiello P, Giotti A, Malcangio M, Bartolini A: Investigation into atropine-induced antinociception. Br J Pharmacol, 1990, 101, 49-54.
16. Giurgea C: The "nootropic" approach to the pharmacology of the integrative activity of the brain. Cond Reflex, 1973, 8, 108-115.
17. Hadjiev D: Asymptomatic ischemic cerebrovascular disorders and neuroprotection with vinpocetine. Ideggyogy Sz, 2003, 56, 166-172.
18. Hara K, Saito Y, Kirihara Y, Sakura S: The interaction between gamma-aminobutyric acid agonists and diltiazem in visceral antinociception in rats. Anesth Analg, 2004, 98, 1380-1384.
19. Kalmari J, Niissalo S, Konttinen YT, Pertovaara A: Modulation of visceral nociceptive responses of rat spinal dorsal horn neurons by sympathectomy. Neuroreport, 2001, 12, 797-801.
20. Kessler J, Thiel A, Karbe H, Heiss WD: Piracetam improves activated blood flow and facilitates rehabilitation of poststroke aphasic patients. Stroke, 2000, 31, 2112-2116.
21. Korzeniewska-Rybicka I, Plaznik A: Role of serotonergic and noradrenergic systems in a model of visceral pain. Pol J Pharmacol, 2001, 53, 475-480.
22. Koster R, Anderson M, De Beer EJ: Acetic acid for analgesic screening. Fed Proc, 1959, 18, 412.
23. Li DP, Chen SR, Pan YZ: Role of presynaptic muscarinic and GABA(B) receptors in spinal glutamate release and cholinergic analgesia in rats. J Physiol, 2002, 543, 807-818.
24. Melis MR Succu S, Mascia MS, Argiolas A, Bernard B: PD-168077, a selective dopamine D4 receptor agonist, induces penile erection when injected into the paraventricular nucleus of male rats. Neurosci Lett, 2005, 379, 59-62.
25. 2A-ARs in the control of nociception, motor behaviour and hippocampal synthesis of noradrenaline. J Pharmacol Exp Ther, 1994, 270, 958-972.
26. Naguib M, Yaksh TL: Antinociceptive effects of spinal cholinesterase inhibition and isobolographic analysis of the interaction with mu and alpha 2 receptor systems. Anesthesiology, 1994, 80, 1338-1348.
27. Nikolova M, Petrova L, Dushkova R: Effect of piracetam in models of experimental inflammation. Int J Tissue React, 1984, 6, 17-21.
28. Nosalova V, Machova J, Babulova A: Protective action of vinpocetine against experimentally induced gastric damage in rats. Arzneimittelforschung, 1993, 43, 981-985.
29. Nuseir K, Proudfit HK: Bidirectional modulation of nociception by GABA neurons in the dorsolateral pontine tegmentum that tonically inhibit spinally projecting nora-drenergic A7 neurons. Neuroscience, 2000, 96, 773-783.
30. Paalzow GH: Noradrenaline but not dopamine involved in NMDA receptor-mediated hyperalgesia induced by theophylline in awake rats. Eur J Pharmacol, 1994, 252, 87-97.
31. Paget GE, Barnes JM. Toxicity tests. In: Evaluation of Drug Activities Pharmacometics. Eds. Laurence DR, Bacharach AL, Academic Press, London, New York, 1964, 1-135.
32. Porsolt RD, Le Pichon M, Jalfre M: Depression: a new animal model sensitive to antidepressant treatments. Nature, 1977, 266, 730-732.
33. Rashid MH, Ueda H: Nonopioid and neuropathy-specific analgesic action of the nootropic drug nefiracetam in mice. J Pharmacol Exp Ther, 2002, 303, 226-231.
34. Sawynok J: Adenosine receptor activation and nociception. Eur J Pharmacol. 1998, 347, 1-11.
35. Serpell M: Role of the sympathetic nervous system in pain. Anaesth Intensive Care Med, 2005, 6, 52-55.
36. Shorvon S: Pyrrolidone derivatives. Lancet, 2001, 358, 1885-1892.
37. Tanabe M, Takasu, K, Kasuya N: Role of descending noradrenergic system and spinal alpha2-adrenergic receptors in the effects of gabapentin on thermal and mechanical nociception after partial nerve injury in the mouse. Br J Pharmacol, 2005, 144, 703-714.
38. Taylor BK, Joshi C, Uppal H: Stimulation of dopamine D2 receptors in the nucleus accumbens inhibits inflammatory pain. Brain Res, 2003, 987, 135-143.
39. Vakulina OP, Iasnetsov VV, Isachenkov VA, Krylova IN, Tishkova IP, Bragin EO, Popkova EV: Effects of piracetam on pain sensitivity and levels of beta-endorphin in blood and cAMP in the cerebral cortex of rats (Russian). Biull Eksp Biol Med, 1990, 109, 163-165.
40. Vas A, Gulyas B, Szabo Z, Bonoczk P, Csiba L, Kiss B, Karpati E, Panczel G, Nagy Z: Clinical and non-clinical investigations using positron emission tomography, near infrared spectroscopy and transcranial Doppler methods on the neuroprotective drug vinpocetine: a summary of evidences. J Neurol Sci, 2002, 203-204, 259-262.
41. Waegemans T, Wilsher CR, Danniau A, Ferris SH, Kurz A, Winblad B: Clinical efficacy of piracetam in cognitive impairment: a meta-analysis. Dement Geriatr Cogn Disord, 2002, 13, 217-224.
42. Wood JN, Boorman JP, Okuse K, Baker MD: Voltage-gated sodium channels and pain pathways. J Neurobiol, 2004, 61, 55-71.
43. Zhang HM, Li DP, Chen, SR: M2, M3, and M4 receptor subtypes contribute to muscarinic potentiation of GABAergic inputs to spinal dorsal horn neurons. J Pharmacol Exp Ther, 2005, 313, 697-704.
44. Zhou X, Dong XW, Crona J, Maguire M, Priestley T: Vinpocetine is a potent blocker of rat NaV1.8 tetrodotoxin-resistant sodium channels. J Pharmacol Exp Ther, 2003, 306, 498-504.